119 related articles for article (PubMed ID: 12767332)
1. Chromatographic purification and properties of a therapeutic human protein C concentrate.
Radosevich M; Zhou FL; Huart JJ; Burnouf T
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 790(1-2):199-207. PubMed ID: 12767332
[TBL] [Abstract][Full Text] [Related]
2. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
[TBL] [Abstract][Full Text] [Related]
3. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Michalski C; Bal F; Burnouf T; Goudemand M
Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
[TBL] [Abstract][Full Text] [Related]
4. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
Burnouf T; Michalski C; Goudemand M; Huart JJ
Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
[TBL] [Abstract][Full Text] [Related]
5. Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography.
Feldman PA; Bradbury PI; Williams JD; Sims GE; McPhee JW; Pinnell MA; Harris L; Crombie GI; Evans DR
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):939-48. PubMed ID: 7893930
[TBL] [Abstract][Full Text] [Related]
6. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C.
Josic D; Hoffer L; Buchacher A
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 790(1-2):183-97. PubMed ID: 12767331
[TBL] [Abstract][Full Text] [Related]
7. Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.
Mousavi Hosseini K; Nasiri S
Med J Islam Repub Iran; 2015; 29():170. PubMed ID: 26034723
[TBL] [Abstract][Full Text] [Related]
8. A method for systematic purification from bovine plasma of six vitamin K-dependent coagulation factors: prothrombin, factor X, factor IX, protein S, protein C, and protein Z.
Hashimoto N; Morita T; Iwanaga S
J Biochem; 1985 May; 97(5):1347-55. PubMed ID: 3161875
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity.
Josić D; Hoffer L; Buchacher A; Schwinn H; Frenzel W; Biesert L; Klöcking HP; Hellstern P; Rokicka-Milewska R; Klukowska A
Thromb Res; 2000 Dec; 100(5):433-41. PubMed ID: 11150587
[TBL] [Abstract][Full Text] [Related]
10. Large-scale preparation of highly purified human C1-inhibitor for therapeutic use.
Poulle M; Burnouf-Radosevich M; Burnouf T
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):543-9. PubMed ID: 7841310
[TBL] [Abstract][Full Text] [Related]
11. A therapeutic, highly purified factor XI concentrate from human plasma.
Burnouf-Radosevich M; Burnouf T
Transfusion; 1992; 32(9):861-7. PubMed ID: 1471251
[TBL] [Abstract][Full Text] [Related]
12. Preparation and properties of a therapeutic inter-alpha-trypsin inhibitor concentrate from human plasma.
Michalski C; Piva F; Balduyck M; Mizon C; Burnouf T; Huart JJ; Mizon J
Vox Sang; 1994; 67(4):329-36. PubMed ID: 7535497
[TBL] [Abstract][Full Text] [Related]
13. [Technology optimization and properties study of factor IV complex concentrates].
Zeng R; Yu R; Li X; Wu Y; Qi H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):142-4. PubMed ID: 15600207
[TBL] [Abstract][Full Text] [Related]
14. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and biological properties of an alpha 1-antitrypsin concentrate.
Burnouf T; Constans J; Clerc A; Descamps J; Martinache L; Goudemand M
Vox Sang; 1987; 52(4):291-7. PubMed ID: 3498260
[TBL] [Abstract][Full Text] [Related]
16. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate.
Burnouf-Radosevich M; Burnouf T
Vox Sang; 1992; 62(1):1-11. PubMed ID: 1580062
[TBL] [Abstract][Full Text] [Related]
17. Purification and preliminary characterization of rabbit vitamin K-dependent coagulation proteins.
Weinstein RE; Rickles FR; Walker FJ
Thromb Res; 1990 Aug; 59(4):759-72. PubMed ID: 2150452
[TBL] [Abstract][Full Text] [Related]
18. Large-scale production and properties of immunoaffinity-purified human activated protein C concentrate.
Orthner CL; Ralston AH; Gee D; Kent R; Kolen B; McGriff JD; Drohan WN
Vox Sang; 1995; 69(4):309-18. PubMed ID: 8751300
[TBL] [Abstract][Full Text] [Related]
19. Purification and some characteristics of the human coagulation factor VII.
Flengsrud R
Eur J Biochem; 1979 Aug; 98(2):455-64. PubMed ID: 114392
[TBL] [Abstract][Full Text] [Related]
20. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
